Experienced in Fibrosarcoma

Dr. Abirami Sivapiragasam

Hematology | Oncology
University Medical Associates Of The Medical University Of South Carol
171 Ashley Ave, 
Charleston, SC 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Fibrosarcoma
University Medical Associates Of The Medical University Of South Carol
171 Ashley Ave, 
Charleston, SC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Abirami Sivapiragasam is a Hematologist and an Oncologist in Charleston, South Carolina. Dr. Sivapiragasam is rated as an Experienced provider by MediFind in the treatment of Fibrosarcoma. Her top areas of expertise are Breast Cancer, Angiosarcoma, Laryngeal Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 22 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in NY
Hospital Affiliations
Musc Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

UNIVERSITY MEDICAL ASSOCIATES OF THE MEDICAL UNIVERSITY OF SOUTH CAROL
171 Ashley Ave, Charleston, SC 29425

Additional Areas of Focus

Dr. Sivapiragasam has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
Enrollment Status: Recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 6 Less Clinical Trials

22 Total Publications

Harnessing Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Opportunities and Barriers to Clinical Integration.
Harnessing Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Opportunities and Barriers to Clinical Integration.
Journal: International journal of molecular sciences
Published: March 21, 2025
Similar Doctors
Advanced in Fibrosarcoma
Dr. Andrea Abbott
Surgical Oncology | General Surgery | Oncology
Advanced in Fibrosarcoma
Dr. Andrea Abbott
Surgical Oncology | General Surgery | Oncology

University Medical Associates Of The Medical University Of South Carol

171 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrea Abbott is a Surgical Oncologist and a General Surgeon in Charleston, South Carolina. Dr. Abbott is rated as a Distinguished provider by MediFind in the treatment of Fibrosarcoma. Her top areas of expertise are Breast Cancer, Retroperitoneal Liposarcoma, Melanoma, Mastectomy, and Lymphadenectomy.

Experienced in Fibrosarcoma
Dr. Kevin D. Becker
Oncology | Hematology
Experienced in Fibrosarcoma
Dr. Kevin D. Becker
Oncology | Hematology

University Medical Associates Of The Medical University Of South Carol

1600 Midtown Ave, 
Mount Pleasant, SC 
 (6.6 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kevin Becker is an Oncologist and a Hematologist in Mount Pleasant, South Carolina. Dr. Becker is rated as a Distinguished provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Familial Wilms Tumor 2, and Clear Cell Sarcoma.

Experienced in Fibrosarcoma
Dr. Scott Lindhorst
Oncology | Neurology | Hematology Oncology
Experienced in Fibrosarcoma
Dr. Scott Lindhorst
Oncology | Neurology | Hematology Oncology

University Medical Associates Of The Medical University Of South Carol

167 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Lindhorst is an Oncologist and a Neurologist in Charleston, South Carolina. Dr. Lindhorst is rated as an Elite provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, Brain Tumor, and Awake Craniotomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sivapiragasam's expertise for a condition
ConditionClose
    View All 58 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile